500
Participants
Start Date
January 1, 2015
Primary Completion Date
June 30, 2019
Study Completion Date
August 31, 2024
Entecavir；Tenofovir Disoproxil Fumarate (TDF)； Tenofovir alafenamide fumarate (TAF)；Interferons
"Entecavir: Participants will receive Entecavir 0.5 mg orally once daily for the duration of the study.~Tenofovir Disoproxil Fumarate (TDF): Participants will receive TDF 300 mg orally once daily for the duration of the study.~Tenofovir alafenamide fumarate (TAF): Participants will receive TAF 25 mg orally once daily for the duration of the study.~Interferon (IFN): Participants will receive IFN 180 µg subcutaneously once weekly for at least 12 weeks."
Tianjin Second People's Hospital
OTHER